FDA approves Xofluza™, the first single-dose oral medicine for influenza

The US FDA has approved Xofluza™, Roche’s (Basel, Switzerland) first-in-class, single-dose oral medicine, for the treatment of acute, uncomplicated influenza in individuals aged 12 or over.

Xofluza has the first novel proposed mechanism of action for treating flu in nearly 20 years, inhibiting polymerase acidic endonuclease – an essential enzyme for viral replication.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment